Biomedical subjects

C Hellesen

Publications and source records attributed to C Hellesen.

9 recordsLinked to original sources

PubMed1987

Soft-laser therapy of rheumatoid arthritis.

The effect of soft-laser therapy on rheumatoid arthritis was evaluated in 17 patients with symmetrical involvement of the metacarpophalangeal joint of the index. Nine treatments with a He-Ne laser, 6 J/cm2, were given on the one hand with a sham irradiation of the other. The study was double-blind. The laser therapy gave some pain relief, but no difference in morning stiffness or joint performance was obtained. It is concluded that the laser therapy is of limited value in rheumatoid arthritis.

Adult↗

PubMed1985

HLA antigen frequencies in juvenile chronic arthritis.

HLA-A, B, C, D, and DR typing was performed in 104 patients with Juvenile Chronic Arthritis (JCA). The majority of these (88 patients) participated in a follow-up study of a series of consecutive patients including patients in remission. The study confirmed that JCA is positively associated with B27, Dw8, and possibly Dw5, and negatively associated with Dw2 and Dw7. In JCA patients in remission, the frequency of Dw4 was significantly decreased to 5.0%, compared with 25.0% in healthy Danes and 23.7% in JCA patients with active disease. In pauciarticular onset JCA, the frequency of Dw4 was significantly decreased to 8.1% compared with 25.0% both in controls and in polyarticular onset JCA. These data indicate that Dw4 may be a risk factor of chronicity and multiple joint involvement in JCA. Chronic iritis was present in 18.2% of Dw8-positive patients, compared with 7.0% in Dw8-negative patients, and the frequency of Dw8 was 50.0% in JCA patients with chronic iritis. Thus, Dw8 may be a risk factor of chronic iritis in JCA. Genetically, three distinct subgroups seem to exist: (i) a B27-associated group; (ii) a D/DR5- and D/DRw8-associated group, and (iii) a D/DR4-associated group.

Adolescent↗

PubMed1984

Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment.

The bone mineral content (BMC) in both forearms (highly correlated to total body calcium) was measured by photon absorptiometry in a representative sample of rheumatoid arthritis outpatients comprising 129 patients treated with either gold salts (n = 29), penicillamine (n = 61), prednisone (n = 24), or other anti-RA drugs (n = 15). The mean BMC value was 84% of normal (p less than 0.001) with the lowest mean value in the group treated with prednisone (73% of normal). The patients as a group had hypocalcaemia (p less than 0.001), raised serum alkaline phosphatase (p less than 0.001), and normal urinary excretion rates of calcium and hydroxyproline. These results indicate that RA patients have disturbances in their calcium and bone metabolism.

Adult↗

PubMed1984

Controlled release indomethacin (Indotard). Clinical trial in patients with rheumatoid arthritis.

In a double-blind, crossover multicentre trial the effect on morning stiffness and occurrence of side effects of a controlled-release indomethacin preparation, Indotard, was compared with a conventional preparation, Indocid. 30 Patients between 38 and 74 years of age--six from each centre--underwent the investigation: A 4-day escalating period and 2 X 7 days' treatment. In the average figures, no difference in effect or side effects could be seen between Indotard 50 mg given twice and Indocid 25 mg given four times daily. There was, however, a marked preference among the younger (less than 62 years) for the controlled-release formulation and a preference among the older for the conventional preparation.

Adult↗

PubMed1970